ReviewFrontiers in endocrinology2026
Metabolic memory in diabetic complications: evidence for persistent cellular states and limits of therapeutic reversal.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic memory is defined here as an exposure-history-dependent cellular phenotype that persists beyond immediate carry-over after verified withdrawal of the initiating exposure, principally high glucose and is accompanied by a specified functional impairment or an altered response to the same defined secondary stimulus. This operational definition separates cellular memory from clinical legacy effects, continuing local stimulation and residual structural injury. We critically examine evidence from longitudinal clinical studies, human biospecimens, animal models and controlled cell experiments, distinguishing molecular persistence, measured signaling activity, causal maintenance and treatment-free durability. DCCT/EDIC and UKPDS establish lasting benefits of earlier glycemic management but do not independently identify cellular memory as the mechanism. Experimental evidence supports selected endothelial redox circuits, epigenetic regulation and hematopoietic progenitor training; human causal evidence is substantially more limited. Persistent chromatin marks do not necessarily imply continuously active signaling, and latent priming may become apparent only after rechallenge. In kidney, cardiovascular, retinal and wound disease, candidate cellular memory coexists with hypoxic or inflammatory niches and structural loss. Pancreatic β-cell plasticity is considered a comparative endocrine model rather than an established complication-memory circuit. The proposed interactions among epigenetic, mitochondrial, metabolic and inflammatory mechanisms remain a framework supported by selected local feedback loops, not a universally demonstrated network. Therapeutic evidence is organized into prevention, modification or suppression of established abnormalities, and sustained molecular and functional recovery after treatment cessation after intervention withdrawal. The latter remains unestablished in patients for the mechanisms reviewed. Early glycemic and multifactorial management remains essential, while mechanistic translation requires explicit recovery, perturbation and post-treatment follow-up designs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.